secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aquestive Therapeutics, Inc. (AQST)
CIK:        0001398733
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001628280-25-001229
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aquestive provides business update; on track to submit Anaphylm NDA in Q1 2025; cash ~$70M
--------------------------------------------------------------------------------

- On track to submit Anaphylm (epinephrine) Sublingual Film NDA to FDA in Q1 2025; potential approval/launch as early as Q1 2026.
- Successfully completed pre-IND meeting for AQST-108 (epinephrine) Topical Gel; Phase 2a in alopecia areata to begin Q2 2025.
- Unaudited cash and cash equivalents approximately $70 million as of Dec 31, 2024.
- Libervant (diazepam) Buccal Film received FDA approval for ages 2-5 and Orphan Drug Exclusivity until April 2031.
- CEO outlines 2025 focus: Anaphylm launch prep, ex-U.S. strategy, AQST-108 Phase 2a, Libervant expansion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1398733/000162828025001229/0001628280-25-001229-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1398733/000162828025001229/aqst-20250113.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-001229

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer